NEUROVANCE, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.neurovance.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
Phase 1
Completed
- Conditions
- Drug UsersHealthy Volunteers
- Interventions
- Drug: EB-1020 400 mgDrug: EB-1020 800 mgDrug: Placebo
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Neurovance, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02144415
- Locations
- 🇺🇸
Vince and Associates Clinical Research, Inc., Overland Park, Kansas, United States
A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
Phase 1
Completed
- Conditions
- Normal, Healthy Volunteers
- Interventions
- Drug: EB-1020 IROther: PlaceboDrug: EB-1020 SR1Drug: EB-1020 SR2Drug: EB-1020 SR3
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Neurovance, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT01744808
- Locations
- 🇦🇺
Nucleus Network Ltd., Melbourne, Victoria, Australia
News
No news found